eyenovia-logo 3
  • myopia
  • mydriasis
  • Glaucoma
  • dry eye
  • Presentations
  • Publications

MicroPine for Myopia:

MicroPine is our proprietary microdose formulation of atropine for progressive myopia (nearsightedness). Myopia develops in childhood and commonly seen in adults. Progressive moderate-to-severe myopia is associated with significant ocular morbidity including increased rate of retinal detachment, choroidal and retinal atrophy, choroidal neovascularization, all of which can lead to irreversible vision loss.  It is estimated there are over 80 million children worldwide and more than 5 million in the US with myopia.

Image

US 5 Million

Chart_Myopia 3

Indication
Pharmacologic Mydriasis

MicroStat is our proprietary first-in-class fixed combination micro-formulation of Phenlyephrine-Tropicamide for mydriasis (eye dilation). There are more than 80 million topical mydriatic applications performed every year (globally or in U.S.) as a required part of the comprehensive dilated eye exam and standard retina fundoscopy for diabetic retinopathy screening, macular degeneration evaluation, glaucoma optic disc evaluation and many other back-of-the-eye conditions.

Pupil-dilation-animated-gif-5_220

US 80M eye exams

Chart_Mydriasis 3

Indication
Chronic Angle Closure Glaucoma

MicroProst is our proprietary prostaglandin micro-formulation developed as first-line indication for CACG. Currently, there are no FDA-approved therapies for CACG, which accounts for 10% and up to 50% of all glaucoma diagnoses in US and China, respectively.

Glaucoma is a chronic disease where patients often require life-long therapy for the control of intraocular pressure. Once approved, MicroProst will be the first treatment indicated for CACG, a disease affecting 581,000 people in the US.

Image

US 581,000

*Addressable Population

Chart_Glaucoma 3

Indication
MicroTears for Dry Eye: 

MicroTears is our highly differentiated micro-droplet ocular surface tear replenishment for the $2 billion (WW?) OTC artificial tear market. Dry Eye Syndrome (“DES”) is a common ocular condition with more than 20 million people in the US suffering from symptoms of dry eye. Twenty-five percent of patients visiting ophthalmology clinics report dry eye symptoms.

eyeDrop-burst-5Loop
Chart_Dry eyes 3

American Academy of Ophthalmology 2017
Dr.Ianchulev, New York Eye and Ear Infirmary

Associate for Research in Vision and Ophthalmology 2016
Dr. Lin, UCSF

[email protected] Association for Cataract and Refractive Surgery 2016
Dr. LaBelle

International Symposium on Ocular Pharmacology
and therapeutics ISOPT 2015
B. Butler

American Academy of Ophthalmology 2014
Dr.Ianchulev

Piezo-print microdosing
AAO Best paper 2014  Download

Therapeutic Delivery 2017
High-precision piezo-ejection ocular microdosing:

Phase II study on local and systemic effects of topical phenylephrine
Read More

Therapeutic Delivery 2016
Pharmacodynamic profile of mydriatic agents delivered by

ocular piezo-ejection microdosing compared with conventional eyedropper
Read More

Comparison Of Ocular Effects After Use Of Topical Eye Drops
Versus Use Of The WhisperTM Topical Drug Applicator
Link

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017    +1 (917) 289-1117

[email protected]